Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent dasatinib showed limited efficacy in unselected populations of breast cancer, including TNBC. To study potent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Gaule, Patricia, Mukherjee, Nupur, Corkery, Brendan, Eustace, Alex J., Gately, Kathy, Roche, Sandra, O’Connor, Robert, O’Byrne, Kenneth J., Walsh, Naomi, Duffy, Michael J., Crown, John, O’Donovan, Norma
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6520724/
https://ncbi.nlm.nih.gov/pubmed/30999598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11040548
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados